Andrés López‐Hernandez

Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non–Germinal Center B-Cell Diffuse Large B-Cell Lymphoma

Anas Younes, Laurie H. Sehn, Peter Johnson et al. · Journal of Clinical Oncology · 2019 · 591 citations · Full text

Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial

H. Miles Prince, Youn H. Kim, Reinhard Dummer et al. · The Lancet · 2017 · 569 citations

Hematological Malignancy, Lymphoid Neoplasia, Medicine +9

Risk, Predictors, and Clinical Characteristics of Lymphoma Development in Primary Sjögren's Syndrome

Roser Soláns-Laqué, Andrés López‐Hernandez, Josep Angel Bosch-Gil et al. · Seminars in Arthritis and Rheumatism · 2011 · 149 citations

Lymphoid Neoplasia, Autoimmune Disease, Sjögren’s Syndrome +9

A phase II study of the survivin suppressant YM155 in patients with refractory diffuse large B‐cell lymphoma

Bruce D. Cheson, Nancy L. Bartlett, Julie M. Vose et al. · Cancer · 2011 · 124 citations · Full text

Validation of the <scp>NCCN</scp>‐<scp>IPI</scp> for diffuse large B‐cell lymphoma (<scp>DLBCL</scp>): the addition of β₂‐microglobulin yields a more accurate <scp>GELTAMO</scp>‐<scp>IPI</scp>

Carlos Montalbán, Antonio Díaz‐López, Iván Dlouhy et al. · British Journal of Haematology · 2017 · 81 citations · Full text